EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy

Kulzhan Berikkhanova iD, Isah Inuwa iD, Abdulrahman Garba Jibo iD, Nurzhan Berikkhanov iD, Nurzhan Bikhanov iD, Yessenkhan Sultan iD, Ardak Omarbekov iD

International Journal of Molecular Sciences · 25.12.2025 · 27 (1) · 248

DOI: 10.3390/ijms27010248 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.12.2025. Verfasst von Kulzhan Berikkhanova und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Genetic Therapy, Nanoparticles. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nazarbayev University, Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan, Nazarbayev University under Collaborative Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the years, cancer has continued to be a leading global health threat, prompting researchers to explore advanced therapies that go beyond traditional treatments like chemotherapy and radiotherapy. Among these advanced therapies, gene therapy and immunotherapy have shown significant promise in treating cancer by either altering genetic makeup or stimulating the immune system. However, their clinical applications face significant obstacles such as poor drug delivery, rapid degradation, and immune system clearance. Hybrid nanocarriers have emerged as a transformative development in modern precision oncology, enabling the co-delivery of gene therapy and immunotherapy agents in a highly targeted manner to address the persistent limitations of traditional cancer treatments. This review focuses on hybrid nanocarrier systems specifically engineered for co-delivery applications and critically evaluates when and how these multifunctional platforms outperform conventional single-modality or non-hybrid formulations. We compare key hybrid architectures in terms of payload compatibility, pharmacokinetics, immune modulation, and translational readiness, and examine the influence of tumor microenvironmental characteristics on their therapeutic performance. Particular emphasis is placed on stimuli-responsive designs, biomimetic surface engineering, and artificial intelligence–assisted optimization as emerging strategies to enhance co-delivery efficacy. By synthesizing current evidence and identifying key scientific and manufacturing gaps, this review aims to provide a practical foundation for advancing hybrid nanocarriers from laboratory development to clinically meaningful, personalized cancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyGenetic TherapyNanoparticlesDrug CarriersHumansAnimalsDrug Delivery SystemsGene Transfer TechniquesTumor Microenvironment

Stichwörter der Autor:innen

cancergene therapyhybrid nanocarriersimmunotherapyprecision oncology

Substanzen

Drug Carriers

Autor:innen und Institutionen

  • National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.
  • University Medical Center, Nazarbayev University, Astana 010000, Kazakhstan.
  • Scientific and Educational Center of Surgery, Astana Medical University, Astana 010000, Kazakhstan.
  • School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.
  • Department of Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
  • Center of Surgery, City Polyclinic № 2, Taraz 080000, Kazakhstan.

ORCID-Profile: Kulzhan Berikkhanova, Isah Inuwa, Abdulrahman Garba Jibo, Nurzhan Berikkhanov, Nurzhan Bikhanov, Yessenkhan Sultan, Ardak Omarbekov

Förderung

  • Nazarbayev University
  • Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan
  • Nazarbayev University under Collaborative Research Program

Zitieren

APA

Berikkhanova, K., Inuwa, I., Jibo, A. G., Berikkhanov, N., Bikhanov, N., Sultan, Y., & Omarbekov, A. (2025). Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy. International Journal of Molecular Sciences, 27(1), 248. https://doi.org/10.3390/ijms27010248

Vancouver

Berikkhanova K, Inuwa I, Jibo AG, Berikkhanov N, Bikhanov N, Sultan Y, et al. Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy. International Journal of Molecular Sciences. 2025;27(1):248. doi:10.3390/ijms27010248

BibTeX
@article{Berikkhanova2025,
  author = {Berikkhanova, Kulzhan and Inuwa, Isah and Jibo, Abdulrahman Garba and Berikkhanov, Nurzhan and Bikhanov, Nurzhan and Sultan, Yessenkhan and Omarbekov, Ardak},
  title = {Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {248},
  doi = {10.3390/ijms27010248}
}
Kostenlos starten →